JAKAVI safety profile in the RESPONSE trial
- In the RESPONSE trial, safety was a secondary endpoint1
- 3.6% of patients treated with JAKAVI discontinued due to adverse events2,3*
Haematologic adverse reactions up to Week 322
Includes new or worsening abnormalities as assessed using laboratory values.2 One patient in the BAT arm withdrew consent and was not treated on study.2
- The majority of nonhaematologic adverse reactions were Grade 1/22
Nonhaematologic adverse reactions up to Week 322
Includes events occurring in ≥10% of patients in either treatment group.2 One patient in the BAT arm withdrew consent and was not treated on study.2
By Week 32, 1 patient receiving JAKAVI and 6 patients receiving BAT experienced a thromboembolic event2†
Types of thromboembolic events by Week 324,5
One patient in the BAT arm withdrew consent and was not treated on study.2 One patient in the BAT arm had both myocardial infarction and pulmonary embolism.5